Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L13a pseudogene 26 (RPL13AP26) is a processed pseudogene in the human genome, derived from the parent gene RPL13A, which encodes a component of the 60S ribosomal subunit[1]. Pseudogenes like RPL13AP26 are genomic DNA sequences similar to normal genes but are nonfunctional; they typically arise through genome duplication or retrotransposition and contain disablements such as premature stop codons or frameshifts that prevent the production of functional proteins[7][10]. RPL13AP26 does not encode any protein product, has no known biological function, is not associated with any disease process, is not used as a biomarker, and is not a therapeutic target[1][4][8]. Alternative names for this locus include RPL13A_13_1745.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L13a pseudogene 26 (RPL13AP26).